Neurocrine Biosciences (NBIX) Operating Leases (2019 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Operating Leases of $461.6 million for Q2 2026, down 5.76% year-over-year from $489.8 million in Q2 2025, and little changed on a QoQ basis from $463.5 million in Q1 2026.
Neurocrine Biosciences (NBIX) Operating Leases (2019 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Operating Leases for 8 years, with the latest figure at $461.6 million in Q2 2026.
- Operating Leases for Q2 2026 came in at $461.6 million, down 5.76% year-over-year; the trailing twelve-month figure through Jun 2026 was $461.6 million (down 5.76% YoY), and the FY2025 annual result was $415.3 million, down 8.75% from the prior year.
- Operating Leases steadied at $461.6 million in Q2 2026, from $463.5 million in the prior quarter.
- Over five years, Operating Leases peaked at $493.1 million in Q1 2025 and troughed at $93.5 million in Q4 2022.
- A 5-year average of $282.0 million and a median of $287.0 million in 2024 frame the typical range for Operating Leases.
- The widest annual swing landed in 2022, when Operating Leases slipped 11.21%; it then jumped 175.99% in 2024.
- A 5-year view of Operating Leases shows it stood at $93.5 million in 2022, then surged by 102.99% to $189.8 million in 2023, then soared by 139.78% to $455.1 million in 2024, then dropped by 8.75% to $415.3 million in 2025, then climbed by 11.15% to $461.6 million in 2026.
- Per Business Quant data, the three most recent Operating Leases figures were $461.6 million in Q2 2026, $463.5 million in Q1 2026, and $415.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 461.60 Mn |
| Mar 31, 2026 | 406.20 Mn |
| Dec 31, 2025 | 415.30 Mn |
| Sep 30, 2025 | 428.40 Mn |
| Jun 30, 2025 | 489.80 Mn |
| Mar 31, 2025 | 493.10 Mn |
| Dec 31, 2024 | 455.10 Mn |
| Sep 30, 2024 | 286.20 Mn |
| Jun 30, 2024 | 291.60 Mn |
| Mar 31, 2024 | 287.90 Mn |
| Dec 31, 2023 | 189.80 Mn |
| Sep 30, 2023 | 85.90 Mn |
| Jun 30, 2023 | 89.10 Mn |
| Mar 31, 2023 | 90.40 Mn |
| Dec 31, 2022 | 93.50 Mn |
| Sep 30, 2022 | 113.90 Mn |
| Jun 30, 2022 | 99.60 Mn |
| Mar 31, 2022 | 119.40 Mn |
| Dec 31, 2021 | 105.30 Mn |
| Sep 30, 2021 | 121.90 Mn |